Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell NVrnSpNpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXfJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJFMvPj[nLUC1JO69VQ>? MXrTRW5ITVJ?
CAL-51 cell Mm\0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2LTUmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjZibl2= NYPke3JkW0GQR1XS
ABC-1 cell M4[wNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlUhdk1? NYDYSm5oW0GQR1XS
A2780 cell M37JXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVQhdk1? MWnTRW5ITVJ?
ES1 cell M4jXZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwN{S5JI5O NVTnT5FxW0GQR1XS
HUTU-80 cell NHLlXWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkXuTY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QTFibl2= NGHKXGtUSU6JRWK=
NCI-H292 cell NH[3[XZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlzJTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDh4IH7N MV3TRW5ITVJ?
NB69 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3HHWWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlIhdk1? MVHTRW5ITVJ?
ES8 cell Mn\pS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV3QNndLUW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMzKG6P NG\tb4tUSU6JRWK=
BCPAP cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3\ENmlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM1KG6P M4K4THNCVkeHUh?=
T-24 cell M1v5PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{TRWGlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVUhdk1? MVHTRW5ITVJ?
EW-16 cell Mmi2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWDJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NUBvVQ>? MoDyV2FPT0WU
OVCAR-5 cell M2DiV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVXJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg{KG6P NWnaclREW0GQR1XS
SF126 cell Mlj6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFvjVldKdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46PSCwTR?= NUfyPW81W0GQR1XS
KP-4 cell M4m1[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1TGdmlvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVchdk1? MYrTRW5ITVJ?
GAMG cell Mn\VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFLiOGFKdmirYnn0bY9vKG:oIHj1cYFvKEeDTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlUyKG6P NYnXPI1QW0GQR1XS
HOS cell NWi5UZVTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3TQUWlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61N{BvVQ>? MWLTRW5ITVJ?
CHL-1 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVO0TXo4UW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDFibl2= NXzIVVNtW0GQR1XS
AGS cell Ml\HS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOE[gcm0> MlPiV2FPT0WU
MDA-MB-157 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIr2Z2lKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0yPTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmyJI5O M{DGdnNCVkeHUh?=
HSC-3 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUnSeGVrUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= NXPZfoduW0GQR1XS
CAL-72 cell NHP3RZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfOR2tJUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytO|Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjB{IH7N NX;pSW0xW0GQR1XS
NBsusSR cell NFTGS3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlzHTY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yOyCwTR?= NXr1WGh[W0GQR1XS
ES7 cell NH62V2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFLib2VKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVkhdk1? NGrZfZRUSU6JRWK=
H-EMC-SS cell MmG4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml63TY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2= MmfIV2FPT0WU
NCI-H1703 cell NYrWZYp3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX:2eZJEUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4ODNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[4JI5O Mk\FV2FPT0WU
BHT-101 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlczKG6P NHTjPGFUSU6JRWK=
SK-OV-3 cell MkDhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc2KG6P NV7vWIFZW0GQR1XS
EW-24 cell MkXJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2fN[2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlg{KG6P MYrTRW5ITVJ?
PSN1 cell M1HWVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWfXUpNZUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45PCCwTR?= NXHmZmhHW0GQR1XS
OVCAR-8 cell M{jGZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1\mNmlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2= MlvYV2FPT0WU
NCI-H1563 cell M4DscWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2= NID0SY5USU6JRWK=
SW756 cell NVW0XFlMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xN{BvVQ>? NWDvU4puW0GQR1XS
A375 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkjYTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xOEBvVQ>? NIPZN5lUSU6JRWK=
Ca9-22 cell Mn\jS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4K2WGlvcGmkaYTpc44hd2ZiaIXtZY4hS2F7LUKyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4zPSCwTR?= MlXwV2FPT0WU
SW1990 cell NFzYVWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV\hWYR2UW6qaXLpeIlwdiCxZjDoeY1idiCVV{G5PVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjN{IH7N M4rKcXNCVkeHUh?=
ES4 cell M2\sZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M33QSmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6zPUBvVQ>? NHTxWo9USU6JRWK=
HCE-T cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnzPTY5pcWKrdHnvckBw\iCqdX3hckBJS0VvVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFUhdk1? MVfTRW5ITVJ?
MOLT-16 cell Mn7VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUfKUHIxUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC53MzDuUS=> NX7oTow5W0GQR1XS
HSC-4 cell NHizV4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV3ofnRtUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQCCwTR?= M{Do[3NCVkeHUh?=
NCI-SNU-1 cell MlXWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2VTmWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQDZibl2= M3TjXnNCVkeHUh?=
EW-11 cell M3jsNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2T5UmlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlkhdk1? MVLTRW5ITVJ?
HT-1080 cell NIP5U|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVLJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk6KG6P NV7ZbZRWW0GQR1XS
MES-SA/Dx5 cells Mmn6R5l1d3SxeHnjbZR6KGG|c3H5 MkW5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUNVODL1T4OUBk\WyuczygTWM2OD13IH7N MV2yN|k{Pzl6MR?=
SW1710 cell NHrxVo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn[yTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlE3KG6P MU\TRW5ITVJ?
EW-1 cell NELsbFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGPq[45KdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI1KG6P NX\aRohbW0GQR1XS
BV-173 cell NYH2bG9yT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVr4dYpsUW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7IH7N M37jZnNCVkeHUh?=
TE-8 cell M3TLVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkSxJI5O NHXrNmdUSU6JRWK=
G-401 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXKyRXR6UW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDNibl2= MVrTRW5ITVJ?
KOSC-2 cell Mmn4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2DLc2lvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PSCwTR?= NVLSUWtPW0GQR1XS
HuCCT1 cell MnzBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4rzVGlvcGmkaYTpc44hd2ZiaIXtZY4hUHWFQ2SxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42OiCwTR?= M1vuUHNCVkeHUh?=
FADU cell NEi1V3lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{X4emlvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOlYhdk1? MlnTV2FPT0WU
MHH-ES-1 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG1JUC2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43QSCwTR?= NVzybFZvW0GQR1XS
ES3 cell NV3Ffpc5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV3y[lFwUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc6KG6P M3z3XHNCVkeHUh?=
OVCAR-4 cell Mn3RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWHjcYxVUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=> Mn\IV2FPT0WU
HD-MY-Z cell M2G4SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlzwTY5pcWKrdHnvckBw\iCqdX3hckBJTC2PWT3aJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46OSCwTR?= M{[2R3NCVkeHUh?=
human JAR cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWjJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwOUegcm0> NEjpSW9USU6JRWK=
A427 cell M3nwTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2CzSGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNFchdk1? M{DaZ3NCVkeHUh?=
697 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYnJcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwMUOgcm0> NWnr[XYzW0GQR1XS
OVCAR-3 cell NH7HVoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnO5TY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zKG6P MV;TRW5ITVJ?
human NB14 cell NVjBZ49zT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEfp[GpKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P M{H4S3NCVkeHUh?=
GB-1 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NITyXGpKdmirYnn0bY9vKG:oIHj1cYFvKEeELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlcyKG6P MnHTV2FPT0WU
COR-L105 cell MnjiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUDnVmVlUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFExPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwN{[gcm0> MVXTRW5ITVJ?
647-V cell MmLGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MofqTY5pcWKrdHnvckBw\iCqdX3hckA3PDdvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uPUBvVQ>? MlrvV2FPT0WU
human K5 cell M33NXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWrJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PyCwTR?= Mlf0V2FPT0WU
DMS-273 cell NXPXO3pUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEPGOJRKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N MULTRW5ITVJ?
UM-UC-3 cell NELhbGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnKxTY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= MVLTRW5ITVJ?
HEL cell MoL2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{DBcGlvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz6wPEBvVQ>? MUDTRW5ITVJ?
human KU-19-19 cell MkTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVXrW|FJUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEmgcm0> NIHtTWZUSU6JRWK=
MC-IXC cell NHrncpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml3kTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlE4KG6P MX;TRW5ITVJ?
human H4 cell M{nuOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVXQeWFmUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNlUhdk1? NY\JSFFRW0GQR1XS
NUGC-3 cell NUSyWndET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnPZTY5pcWKrdHnvckBw\iCqdX3hckBPXUeFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM{KG6P MnTkV2FPT0WU
CHP-212 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;kSIZKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjN2IH7N NHLoRYVUSU6JRWK=
human SW982 cell NIf2N4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1vlVGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlQ1KG6P MUnTRW5ITVJ?
C-33-A cell NGSxdWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3rrbWlvcGmkaYTpc44hd2ZiaIXtZY4hSy1|Mz3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{42QCCwTR?= MXvTRW5ITVJ?
PC-3 cell NI\WNnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYW5OYxmUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?= NHjKUI5USU6JRWK=
COLO-684 cell MnGzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2[2dGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22PFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjJzIH7N Mnv3V2FPT0WU
SNU-387 cell MnrXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{jYPGlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUO4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvPDlibl2= MULTRW5ITVJ?
U251 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGG0cJBKdmirYnn0bY9vKG:oIHj1cYFvKFV{NUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25Mlg3KG6P NXHoPW5VW0GQR1XS
A673 cell MlnzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXPPS2NQUW6qaXLpeIlwdiCxZjDoeY1idiCDNkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPiCwTR?= NVG3[pRlW0GQR1XS
human T47D cell NH7qXXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWDJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNj63PUBvVQ>? NH6zZpBUSU6JRWK=
A549 cell NVP1b3RMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M13aWWlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlYhdk1? NWLER3o5W0GQR1XS
PC-14 cell NHr3WmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIPTPHhKdmirYnn0bY9vKG:oIHj1cYFvKFCFLUG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvPzNibl2= NUHweplYW0GQR1XS
A704 cell NWG4[4R1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4m0XmlvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK3MlQ2KG6P NHf5dGpUSU6JRWK=
MCF7 cell NH;4VFdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4PRUmlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOxMlM3KG6P NYfHcVFOW0GQR1XS
PC3 cells NGW2T5FHfW6ldHnvckBie3OjeR?= MmrkTY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN|A5KHKnc3nkeYUhcW5iaIXtZY4hWEN|IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTF|IN88US=> M3;pOVIyOzRzNke1
F-36P cells NXHFOGR2WHKxbHnm[ZJifGmxbjDhd5NigQ>? MlHhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCILUO2VEBk\WyuczygTWM2OD1yLkK4JO69VQ>? M{DUWVIyOzRzNke1
OCI-AML2 cells NXzNNYlVWHKxbHnm[ZJifGmxbjDhd5NigQ>? NF\UbVVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;DTU1CVUx{IHPlcIx{NCCLQ{WwQVAvOzVizszN Mm\sNlE{PDF4N{W=
K562 cells NV62TmQxWHKxbHnm[ZJifGmxbjDhd5NigQ>? NX;XOlNTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>? MYOyNVM1OTZ5NR?=

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Unknown status Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID